Esther Cho - 24 Feb 2026 Form 4/A - Amendment Insider Report for Keros Therapeutics, Inc. (KROS)

Reporting relationship: Chief Legal Officer
Issuer ticker: KROS
Reported as of: 24 Feb 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 27 Mar 2026, 16:15:14 UTC
Original report date: 26 Feb 2026
Prior SEC filing: 20 Feb 2026
Next SEC filing: 20 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Esther Cho

Key filing fact

Esther Cho filed Form 4/A - Amendment for Keros Therapeutics, Inc. (KROS) on 27 Mar 2026.

Key facts

This page summarizes Esther Cho's Form 4/A - Amendment filing for Keros Therapeutics, Inc. (KROS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Mar 2026, 16:15.

Change

Previous filing in this sequence was filed on 20 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0002081460 Primary reporting owner

Cho Esther

Relationship: Chief Legal Officer
Address: C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON
Signature: /s/ Esther Cho
Signature date: 27 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KROS transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +80,000
Change %
Price: $0.000000^*
Shares after: 80,000
Date: 24 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,000
Exercise price: $15.52
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2027, and the remaining shares subject to the option shall vest in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC remarks

This filing amends and restates the Form 4 filed on February 26, 2026 that erroneously reported a Date of Earliest Transaction of January 5, 2026 due to an error with the filing platform.